- AuthorisedTherapeutic exploratory (Phase II)
RENAISSANCE 2: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of SPN-817 in Adults with Focal Onset Seizures
This study is testing a new medicine, SPN-817, for adults who have focal onset seizures. We want to see if it helps reduce seizures and if it's safe. Some people will get the new medicine, and others will get a dummy medicine to compare the effects.
For: Focal Onset SeizuresPoland · Hungary · Bulgaria - Ongoing, recruitingTherapeutic use (Phase IV)
The OPTIMIzE study;OPen label multicenter randomized Trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de novo renal transplantation in Elderly patients.
This study looks at new ways to give medicines after a kidney transplant to elderly patients. It compares standard treatment with a different combination of drugs to see which works best for protecting the new kidney and keeping patients healthy.
For: kidney transplantNetherlands · Belgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
A 12-Month, Randomized, Controlled, Open-Label, Dose Escalation Study Evaluating Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of an Anti-CD2 Monoclonal Antibody, TCD601(siplizumab) Compared to Anti-Thymocyte Globulin (rATG), as Induction Therapy in de novo Renal Transplant Recipients
This study looks at a new medicine called TCD601 (siplizumab) for people who have recently had a kidney transplant. It compares TCD601 to a standard treatment to see if it's safe and how well it helps prevent the body from rejecting the new kidney.
For: Renal TransplantationSweden · Spain · Austria